Introduction
Breast cancer 1, early onset (BRCA1) is a tumor suppressor. The BRCA1 protein has a molecular weight of 220 kDa (Clark et al., 2012) and is coded with the 85-kb BRCA1 gene located on chromosome 17q (Barker et al., 1996; Tan-Wong et al., 2008) . Mutations in the BRCA1 gene induce the early onset of hereditary forms of breast cancer (BC) and ovarian cancer (OC) . At the molecular level mutations in the BRCA1 gene lead to the synthesis BRCA1 protein with compromised function in homologous recombination-dependent DNA repair. Homologous recombination-dependent DNA repair is the main function of BRCA1 and its failure leads to chromosomal instability and further on to the development of oncologic diseases (Moynahan et al., 1999) . Multiple proteins are involved in BRCA1 functioning, altogether forming the BRCA1 tumor suppressor network (Jiang and Greenberg, 2015) .
The development of sporadic BC and OC due to the inhibition of BRCA1 function could be the result, on one hand, of BRCA1 gene mutation accumulation leading to the formation of nonfunctional protein product, and on the other hand, of more frequent epigenetic inhibition of BRCA1 expression. The latter event could be caused by DNA methylation in the promoter region of the BRCA1 gene as well as by covalent modifications of nucleosome histone proteins in the promoter and coding regions of the BRCA1 gene. Table) that include in the N-terminus the RING domain, which binds to BARD1 (Wu et al., 1996) . The BARD1 protein participates in most BRCA1 functions and has similar overall structure consisting of a RING domain, two nuclear localization signals (NLS), and two BRCT domains. The BRCA1 RING domain is followed by exon 11, which does not possess defined structural domains, although it contains two NLS and binding sites for Rad51 and Rad50, which play an important role in DNA double strand break (DSB) repair (Scully et al., 1997; Zhong et al., 1999) . Exon 11 contains also binding sites for tumor suppressor Rb (Aprelikova et al., 1999) and transcriptional factor c-Myc with strong oncogenic activities (Wang et al., 1998) . Downstream from exon 11 and partially overlapping it, there is the coiled-coil domain that is involved in the binding of another tumor suppressor, BRCA2, through PALB2 (Sy et al., 2009 ). This region is also a target of ATM and ATR checkpoint kinases. Finally, at the C-terminus of the BRCA1 protein two BRCT domains are located that present phosphoprotein binding modules (Leung and Glover, 2011) . BRCA1 tandem BRCT domains could interact with the three mutually exclusive protein complexes, each of which participates in the DNA DSB repair pathway, namely the Abraxas/RAP80-containing complex (Kim et al., 2007; Liu et al., 2007 (Kim et al., 2007; Liu et al., 2007; Wang et al., 2007) BACH1 (BRIP1, FANCJ), TopBP1, BLM (Manke et al., 2003; Yu et al., 2003) CtIP, Mre11-Rad50-Nbs1 (MRN) (Yu and Chen, 2004) Wang et al., 2007), BACH1-containing complex (Manke et al., 2003; Yu et al., 2003) , and CtIP-containing complex (Yu and Chen, 2004) . The protein composition of each of these complexes is presented in the Table. BRCA1 plays an important role in the repair of DNA DSB through the error-free homologous recombination. In this regard it is important to mention that proper functioning of BRCA1 in homologous recombination is strongly correlated with its role in BC suppression Moynahan et al., 2001; Walsh and King, 2007; Hu et al., 2011) . One of the most striking examples of the inhibition of BRCA1 function leading to chromosome instability is the appearance of radial chromosomal structures (Silver et al., 2007; Hu et al., 2011) .
BRCA1 consists of several domains (Figure 1,
3. Mechanisms of inhibition of BRCA1-dependent homologous recombination 3.1. BRCA1 mutations leading to the inhibition of DNA repair Mutations in the BRCA1 gene predispose to the development of basal-like BCs with high metastasis and poor prognosis (Bai et al., 2014) . In general, the causes of 5%-10% of BCs and OCs are hereditary mutations in the BRCA1 gene, while 90%-95% of BCs and OCs are sporadic forms of these diseases (Wong-Brown et al., 2015) . In 20% of a subtype of BC, triple negative BC, the patients carry germline mutations in the BRCA1 gene (Weberpals et al., 2008) . However, not all, but only certain, clinically relevant mutations in the BRCA1 gene lead to the development of BC and OC. Moreover, in contrast with other tumor suppressor genes, somatic mutations in the BRCA1 gene are quite rare and are not the main cause of sporadic BC and OC development. For example, in the case of sporadic epithelial OC, the BRCA1 gene mutations are detected in 9% of cases (Hosking et al., 1995) . These facts suggest that at least some part of sporadic forms of BC and OC is due to the epigenetic inhibition of BRCA1 expression that leads to reduced levels of BRCA1 protein product, and therefore to insufficient BRCA1 protein function in homologous recombination, and finally to the development of cancer.
Epigenetic mechanisms of BRCA1 expression regulation
In this section data are presented demonstrating epigenetic inhibition of BRCA1 expression due to covalent modification of DNA and chromatin histone proteins as well as deregulation of BRCA1 expression with transcription factors that altogether are involved in the development of sporadic forms of BC and OC.
One of the important mechanisms of BRCA1 expression inhibition is the methylation of CpG islands in the promoter and coding regions of the BRCA1 gene. Increases in CpG island methylation in the BRCA1 gene were repeatedly demonstrated in BC and OC tissue samples (Esteller et al., 2000; Rice et al., 2000; Esteller et al., 2001; Turner et al., 2007; Wong et al., 2011) . DNA methylation is a stable modification that is maintained during mitotic divisions of cells (Jones and Liang, 2009; Sharma et al., 2011) . Inhibition of BRCA1 gene expression as well as of a series of other tumor suppressor genes induced by DNA methylation could be reversed with directed binding of demethylating enzymes to target genes (De Groote et al., 2012; Chen et al., 2014) .
Another important mechanism of BRCA1 expression regulation is the binding of transcription factors to the BRCA1 gene promoter, which could lead to the inhibition or activation of this tumor suppressor expression in BC and OC (Figure 2 ). In human BRCA1 locus the BRCA1 gene start site is located close (218 bp) to the start site of the NBR2 gene and these two genes are transcribed in opposite directions (Dimitrov et al., 2001; McCoy et al., 2003a; Mueller and Figure  2B ). Another important regulatory element in the BRCA1 promoter is the E2F binding site, which interacts either with the repressors of BRCA1 expression, E2F6 and p53, or the activator of BRCA1 expression, E2F1 (MacLachlan et al., 2000; Oberley et al., 2003;  Figure 2B ). Binding of 53BP1 to the site adjacent to the E2F element also positively regulates BRCA1 expression (Rauch et al., 2005 ; Figure 2B ). Moreover, SET1A, an H3K4 methyltransferase, and BAT3, a cochaperone recruiter, together with an insulator DNA-binding protein, BORIS, bind to the upstream promoter region of the BRCA1 gene and activate it (Nguyen et al., 2008) . Data obtained in the mentioned studies point out to the precise mechanism of action of transcription factors that include epigenetic modification of nucleosomal histones and chromatin remodeling during BRCA1 synthesis inhibition in BC and OC.
In BC and OC BRCA1 gene expression regulation could take place also at the level of covalent modifications of histones, a structural part of the nucleosome which, in turn, is a basic unit of chromatin (Lee and Lee, 2012) . In Figure 3 the key histone H3/4 and H2A/H2B covalent modifications are depicted including acetylation, methylation, phosphorylation, and ubiquitination. Acetylation, methylation, and phosphorylation are ubiquitous modifications characteristic for the N-terminal protrusions of histones H3, H4, H2A, and H2B. Ubiquitination is a more common modification of the C-terminal protrusions of histones H2A and H2B. However, there is a limited number of studies analyzing particular histone modifications at the BRCA1 gene promoter and coding region that may be due to complicated combinatorial nature of histone modifications, usually revealed with chromatin immunoprecipitation (ChIP) and immunoblotting techniques. Some research works address the total acetylated/deacetylated state of chromatin in tumor cells in relation with BRCA1 function. It was demonstrated that in chemoresistant head and neck squamous cell carcinoma, tumor cells had reduced nuclear size, cytoplasmic localization of BRCA1, reduced levels of BRCA1 protein, and deacetylated histone H3 (Lys 9), corresponding to chromatin condensation (Almeida et al, 2014) . Therefore, the observed chromatin condensation results in the inhibition of BRCA1 gene transcription and also could prevent the intercalation of cisplatin in the DNA structure and the access of BRCA1 to sites of DNA damage. In addition to the several mechanisms of BRCA1 expression inhibition described earlier in this review, the loss of heterozygosity (LOH) also could lead to complete disappearance of tumor suppressor BRCA1 in cells (Russel et al., 2000) .
Moreover, recently it was demonstrated that the BRCA1 gene could be amplified in oral squamous cell carcinoma (Ribeiro et al., 2014) . BRCA1 gene amplification could lead to aberrant increase of BRCA1 protein synthesis, therefore changing BRCA1 functioning in homologous recombination.
It is also important to note that the 85-kb BRCA1 gene located on chromosome 17q forms loops between the promoter, intron, and terminator regions. Loop formation between these regions is dynamically regulated depending on the transcriptional status of the BRCA1 gene (Tan- Wong et al., 2008) . Not only a decrease in BRCA1 protein expression, but also an exaggerated increase in BRCA1 protein levels could lead to chromosomal instability and cancer development (Hu et al., 2011 ). Therefore, endogenous native level of BRCA1 expression is necessary for the maintenance of proper BRCA1 functioning in homologous recombination in order to achieve chromosomal stability and cellular homeostasis.
Role of BRCA1 in BC stem cells (BCSCs) development
Recently several reports were published demonstrating that BRCA1 has an important role in the regulation of growth, proliferation, and differentiation of BCSCs, which are often referred to as BC stem-like cells and mammary luminal stem cells (MLSCs) (Bai et al., 2014; Gilabert et al., 2014; Pickholtz et al., 2014) . On one hand, it was known that the germline mutation in BRCA1 causes luminalto-basal mammary tumor transformation. On the other hand, the deletion of p18 (Ink4c)(p18) inhibits CDK4 and CDK6, inactivates the RB pathway, and stimulates MLSC proliferation, finally leading to spontaneous luminal tumor development. In a study by Bai et al. (2014) it was shown that the disruption of BRCA1 by germline or epitheliumspecific mutation on p18-deficient background activates the epithelial-to-mesenchymal transition (EMT) in mice and induces dedifferentiation of MLSCs, which is associated with the expansion of basal and cancer stem cells and the formation of basal-like tumors. The authors revealed the molecular mechanisms of BRCA1 function in the inhibition of EMT. BRCA1 inhibits the EMT in mammary tumor cells via binding to the TWIST promoter and suppressing its activity. The increase in TWIST expression and EMT correlated with the decrease in BRCA1 expression. Taken together, for the first time the authors presented genetic evidences that BRCA1 suppressed TWIST, EMT, and MLSC dedifferentiation and repressed the expansion of basal stem cells and basal-like tumors during BC-genesis.
Another molecular mechanism of BRCA1-dependent growth inhibition of BC stem-like cells and BC cells was described by Pickholtz et al. (2014) . In this work it was demonstrated that BRCA1 in the presence of vitamin D binds to vitamin D responsive elements at the p21waf1 promoter, inducing the acetylation of histone H3 and H4 at this promoter that leads further to increased expression of p21waf1 followed by growth inhibition of both BC stem-like cells and BC cells.
In one more study (Gilabert et al., 2014) it was demonstrated that aldehyde dehydrogenase (ALDH) containing cells are enriched in BCSCs. In ALDH+ BCSCs the overexpression of poly(ADP-ribose) polymerase 1 (PARP1) contributed to the resistance to PARP inhibitors such as olaparib. Particularly high expression of PARP1 was found in ALDH+ cells from BRCA1-mutated HCC1937 and these cells demonstrated resistance to the specific PARP1 inhibitor, olaparib.
5. BRCA1 is a prognostic marker of disease course and a predictive marker of platinum-based chemotherapy efficiency In recent years it has become clear that BRCA1 could serve as a biomarker for several types of cancer. In order for a particular molecule to be a biomarker, it should have a defined biological function, there should be method(s) to measure its quantity, and patient cohorts of reasonable size should be available to study its prognostic and predictive value. BRCA1 protein and BRCA1 mRNA fit well into this definition as BRCA1 protein and mRNA expression levels are prognostic factors of disease course (Wilson et al., 1999; Wang et al., 2004; Al-Mulla et al., 2005; Thrall et al., 2006; Tulchin et al., 2013; Shilpa et al., 2014) . Moreover, patients with BC and especially OC are the subjects of neoadjuvant and adjuvant platinum-based chemotherapy. It is worth to note that patients with altered BRCA1 expression usually are more sensitive to chemotherapeutic platinum-containing compounds including cisplatin, carboplatin, and oxaliplatin (Quinn et al., 2007; Byrski et al., 2009; Silver et al., 2010; Carser et al., 2011; Weberpals et al., 2011; Byrski et al., 2014) . The structure of these commonly used platinum-containing compounds is presented in Figure 4 . These compounds could easily disturb the DNA structure, intercalating between the bases. Carboplatin and oxaliplatin are especially efficient due to the presence of heterocycles in their structure. Diminished BRCA1 protein levels could lead to decreased restoration of the native DNA structure due to the lack of BRCA1-dependent activity that removes the DNA cross-linked adducts. This would lead to increased deleterious effects of platinum-based compounds towards cancer cells, and therefore would increase the efficiency of platinum-based chemotherapy.
Many recent studies demonstrated that BRCA1 expression on mRNA and the protein level could be a powerful prognostic marker of disease course and a predictive marker of platinum-based chemotherapy efficiency.
Conclusion
The review of multiple data on the epigenetic mechanisms of tumor suppressor BRCA1 expression regulation sheds light on its fine-tuning function in homologous recombination and clarifies some aspects of the sophisticated mechanisms of cancer development, especially involving cancer stem cells. The multifaceted regulation of BRCA1 expression includes multiple mechanisms, among which are epigenetic regulation on the level of DNA and histone covalent modifications, regulation with transcriptional factors, LOH, and potentially gene amplification.
Moreover, based on its multiple and important functions in cells and on developing methods for its detection, BRCA1 is arising as a powerful prognostic marker of the course of several cancers, in particular BC and OC, and as a predictive marker of the efficiency of platinum-based chemotherapy for these diseases.
